Der Onkologe

, Volume 16, Issue 9, pp 898–900 | Cite as

Systemtherapie von Gallenwegskarzinomen

Leitthema
  • 54 Downloads

Zusammenfassung

Die Therapie der Gallenwegskarzinome ist multimodal. Je nach Lokalisation und Ausbreitungsmuster beinhaltet sie neben lokal palliativen Maßnahmen auch die systemische Chemotherapie. Die Wirksamkeit von 5-FU, Gemcitabin und Platinanaloga ist durch mehrere nichtrandomisierte Studien belegt. Die Kombination aus Gemcitabin und Cisplatin verlängerte das mediane Überleben im Vergleich zu Gemcitabin in einer aktuellen großen randomisierten Phase-III-Studie signifikant um 3,6 Monate.

Schlüsselwörter

Gallenwegskarzinome Palliative Therapie Systemische Chemotherapie Gemcitabin Cisplatin 

Systemic therapy of cholangiocarcinoma

Abstract

The therapy of cholangiocarcinoma is multimodal and includes systemic chemotherapy in addition to local palliative measures depending on the localization and the pattern of spreading. The effectiveness of 5-fluorouracil, gemcitabine and platinum analogues has been confirmed by several non-randomized studies. In a current large randomized phase III study the combination of gemcitabine and cisplatin significantly extended the average survival by 3.6 months compared to gemcitabine.

Keywords

Cholangiocarcinoma Palliative therapy Systemic chemotherapy Gemcitabine Cisplatin 

Notes

Interessenkonflikt

Der korrespondierende Autor weist auf folgende Beziehungen hin: Vortragshonorare Merck KgaA, Roche

Literatur

  1. 1.
    Dwary AD, Sharma A, Mohanti BK et al (2009) A randomized controlled trial (RCT) comparing best supportive care (BSC), 5 FU plus folinic acid (FUFA) and, gemcitabine plus oxaliplatin (Gem-Ox) in management of unresectable gallbladder cancer (GBC). J Clin Oncol 27: suppl. abstract 4521Google Scholar
  2. 2.
    Eckel F, Brunner T, Jelic S (2010) Biliary cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 21:v65–v69CrossRefPubMedGoogle Scholar
  3. 3.
    Eckel F, Schmid RM (2007) Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. Br J Cancer 96:896–902CrossRefPubMedGoogle Scholar
  4. 4.
    Glimelius B, Hoffman K, Sjoden PO et al (1996) Chemotherapy improves survival and quality of life in patients with advanced pancreatic and biliary cancer. Ann Oncol 7:993–600Google Scholar
  5. 5.
    Hezel AF, Deshpande V, Zhu AX (2010) Genetics of biliary tract cancers and emerging targeted therapies. J Clin Oncol 28:3531–3540CrossRefPubMedGoogle Scholar
  6. 6.
    Hezel AF, Zhu AX (2008) Systemic therapy for biliary tract cancers. Oncologist 13:415–423CrossRefPubMedGoogle Scholar
  7. 7.
    Malka D, Trarbach T, Fartoux L et al (2009) A multicenter, randomized phase II trial of gemcitabine and oxaliplatin (GEMOX) alone or in combination with biweekly cetuximab in the advanced biliary cancer: Interim analysis of the BINGO trial. J Clin Oncol 27: suppl. abstract 4520Google Scholar
  8. 8.
    Okusaka T, Nakachi K, Fukutomi A et al (2010) Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br J Cancer [Epub ahead of print]Google Scholar
  9. 9.
    Sharma A, Mohanti B, Raina V et al (2010) A phase II study of gemcitabine and oxaliplatin (Oxigem) in unresectable gall bladder cancer. Cancer Chemother Pharmacol 65:497–502CrossRefPubMedGoogle Scholar
  10. 10.
    Valle J, Wasan H, Palmer DH et al (2010) Cisplatin plus Gemcitabine versus Gemcitabine for biliary tract cancer. N Engl J Med 362(14):1273–1281CrossRefPubMedGoogle Scholar
  11. 11.
    Williams KJ, Picus J, Trinkhaus K et al (2010) Gemcitabine with carboplatin for advanced biliary tract cancers: a phase II single institution study. HPB (Oxford) 12:418–426Google Scholar
  12. 12.
    Wolpin BM, Mayer RJ (2010) A step forward in the treatment of advanced biliary tract cancer. N Engl J Med 362(14):1335–1338CrossRefPubMedGoogle Scholar
  13. 13.
    Zhu AX, El-Khoueiry A, Llovet JM (2009) Accomplishments in 2008 in the management of hepatobiliary cancers. Gastrointest Cancer Res 3:S28–S36PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  1. 1.Medizinische Klinik und Klinik für Hämatologie und OnkologieCaritasklinik St. TheresiaSaarbrückenDeutschland

Personalised recommendations